Latest Ratios: P/E Ratio -1.7x · EV/EBITDA N/A · ROE -75.5%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $30M | $16M | $25M | $22M | $13M | $46M | $22M | $26M | $34M | $31M | $19M |
| Enterprise Value | $14M | $201820 | $9M | $-385710 | $-18563600 | $23M | $6M | $13M | $24M | $2M | $11M |
| P/E Ratio → | -1.71 | — | — | — | — | — | — | — | — | 1.37 | — |
| P/S Ratio | 175.16 | 95.05 | 24.82 | — | — | — | — | — | — | — | 0.53 |
| P/B Ratio | 1.95 | 1.11 | 0.85 | 0.46 | 0.20 | 0.51 | 0.68 | 1.26 | 0.92 | 0.63 | 4.56 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.19 | 8.75 | — | — | — | — | — | — | — | 0.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.1% | 14.1% | 100.0% | — | — | — | — | — | — | — | 11.8% |
| Operating Margin | -10711.2% | -10711.2% | -2240.9% | — | — | — | — | — | — | — | -88.8% |
| Net Profit Margin | -9756.5% | -9756.5% | -1998.5% | — | — | — | — | — | — | — | -92.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.5% | -75.5% | -51.8% | -36.5% | -68.5% | -44.2% | -30.9% | -69.3% | -36.9% | 84.7% | -238.8% |
| ROA | -62.9% | -62.9% | -44.6% | -32.6% | -63.8% | -41.3% | -25.8% | -56.0% | -30.0% | 39.9% | -59.9% |
| ROIC | -229.7% | -229.7% | -86.8% | -64.1% | -84.1% | -51.6% | -120.4% | -87.0% | -52.7% | -238.7% | -295.7% |
| ROCE | -82.7% | -82.7% | -57.8% | -44.8% | -72.4% | -46.5% | -71.3% | -66.8% | -36.5% | -63.9% | -91.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.05 | — | 0.00 | 1.67 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.09 | -0.55 | -0.47 | -0.48 | -0.26 | -0.49 | -0.64 | -0.27 | -0.58 | -1.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -3397.40 | -73.04 | -15.87 |
Net cash position: cash ($16M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.76 | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 | 10.08 | 4.35 | 7.85 | 6.56 | 1.26 |
| Quick Ratio | 5.76 | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 | 10.08 | 4.35 | 7.85 | 6.02 | 1.08 |
| Cash Ratio | 5.20 | 5.20 | 5.57 | 7.67 | 10.85 | 21.00 | 9.86 | 4.21 | 7.66 | 5.91 | 0.75 |
| Asset Turnover | — | 0.01 | 0.03 | — | — | — | — | — | — | — | 0.68 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.07 | 0.13 |
| Days Sales Outstanding | — | 1502.94 | 328.50 | — | — | — | — | — | — | — | 1.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 80.9% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 73.0% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 80.9% |
| Shares Outstanding | — | $9M | $8M | $8M | $5M | $4M | $1M | $688333 | $645933 | $597933 | $436550 |
Imminent capital funding shortfall
According to current market data, Lisata trades at a P/S multiple of 179.99, a figure that appears disconnected from fundamental performance and reflects extreme investor optimism regarding the future clinical success of the CendR platform rather than any tangible, recurring revenue streams currently generated by the firm.
The lack of a meaningful P/E or EV/EBITDA ratio underscores the company's pre-commercial status, where valuation is driven entirely by binary clinical outcomes. Investors should monitor whether this premium holds as cash reserves deplete, as the current multiple implies a high probability of successful commercialization that remains unproven.
Based on reported financial figures, the company's ROIC has consistently trended in negative territory, reaching -81.5% in 2025Q2, which suggests that the firm is currently destroying shareholder capital as it funds high-cost clinical trials without any offsetting returns from its underlying research and development activities.
The volatility in ROIC, ranging from -19.7% to -81.5% over the last ten quarters, highlights the inefficiency of capital allocation during this developmental phase. This trend warrants further investigation into whether management can improve capital efficiency through strategic partnerships before the current cash runway is fully exhausted.
As reported in recent SEC filings, the company's current ratio has declined from 9.42 in 2024Q2 to 4.23 in 2026Q1, indicating that while the firm maintains a superficial liquidity cushion, the rapid depletion of cash reserves relative to ongoing operating expenses suggests a tightening financial position.
The quick ratio mirrors the current ratio, confirming that the company lacks significant inventory or other non-liquid assets to provide a safety net. This liquidity profile appears increasingly vulnerable, suggesting that the firm may face significant pressure to raise capital in the near term to maintain operations.
While investors often utilize the P/B ratio of 2.00 to assess value, this metric is fundamentally misapplied to Lisata because the company's book value is primarily composed of cash rather than productive operating assets, thereby obscuring the true risk of clinical failure and the lack of tangible collateral.
A more appropriate metric for this business model would be the cash-to-burn ratio or the estimated runway in months, as these provide a clearer picture of the firm's survival horizon. Relying on P/B ignores the reality that the company's intellectual property value is binary and currently lacks a market-validated commercial foundation.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LSTA stock.
Lisata Therapeutics, Inc.'s current P/E ratio is -1.7x. The historical average is 1.4x.
Lisata Therapeutics, Inc.'s return on equity (ROE) is -75.5%. The historical average is -90.3%.
Based on historical data, Lisata Therapeutics, Inc. is trading at a P/E of -1.7x. Compare with industry peers and growth rates for a complete picture.
Lisata Therapeutics, Inc. has 14.1% gross margin and -10711.2% operating margin.